Plasma Lactoferrin Concentration in Acute Non-Lymphocytic Leukaemia (ANLL)

Area of Science:

• Hematology
• Oncology
• Biochemistry

Background:

• Acute non-lymphoblastic leukemia (ANLL) is a serious hematologic malignancy.
• Prognostic markers are crucial for tailoring ANLL treatment strategies.
• Lactoferrin, an iron-binding protein, has immunomodulatory functions.

Purpose of the Study:

• To investigate the association between plasma lactoferrin concentration and clinical outcomes in ANLL patients.
• To explore the relationship between lactoferrin levels, blast counts, and remission rates.

Main Methods:

• Plasma lactoferrin levels were measured in 46 ANLL patients.
• Lactoferrin concentrations were categorized as elevated (>450 μg/L), normal (100-450 μg/L), or low (<100 μg/L).
• Correlation with complete remission (CR) rates, blast cell counts, and polymorph counts was analyzed.

Main Results:

• 17% of patients exhibited elevated plasma lactoferrin.
• Elevated lactoferrin was associated with significantly lower CR rates (12.5% vs. 71%).
• High lactoferrin correlated with increased peripheral blast counts and decreased polymorph counts.

Conclusions:

• Elevated plasma lactoferrin may serve as a negative prognostic indicator in ANLL.
• High lactoferrin levels suggest a poor response to treatment and potential for death in aplasia.
• These findings indicate that elevated lactoferrin might identify ANLL patients with limited hematopoietic reserve.